SCHEMBL273128

SCHEMBL273128

CC1(C)Cc2cccc(C=O)c2O1

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.48
PKM P14618 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 3/20 0.40
POLB P06746 2/20 0.40
NPC1 O15118 2/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2599723 0.83 LMNA (0.37) LMNAPKMNPSR1ALDH1A1KDM4E
SCHEMBL2011873 0.79 LMNA (0.45) LMNAPKMNPSR1ALDH1A1KDM4E
SCHEMBL12191288 0.77 ERN1 (0.37) LMNAALDH1A1POLBNPC1KMT2A
SCHEMBL5961698 0.77 LMNA (0.51) LMNAPKMNPSR1ALDH1A1KDM4E
SCHEMBL4239500 0.76 MEN1 (0.35) LMNAALDH1A1KDM4EMAPTKMT2A
SCHEMBL10892120 0.76 LMNA (0.58) LMNAALDH1A1KDM4EMAPTPOLB
SCHEMBL2435227 0.75 LMNA (0.34) LMNAALDH1A1KDM4EMAPTNPC1
SCHEMBL4560481 0.75 LMNA (0.39) LMNAPKMNPSR1ALDH1A1KDM4E
SCHEMBL12035984 0.75 ERN1 (0.40) LMNANPSR1ALDH1A1KDM4EMAPT
SCHEMBL435089 0.74 LMNA (0.49) LMNAPKMNPSR1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3523277-B1 SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS ABBVIE OVERSEAS SARL (LU) 2021-06-30 EP disclosed
EP-3523293-B1 SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS ABBVIE OVERSEAS SARL (LU) 2021-06-16 EP disclosed
US-20190315687-A1 Substituted Pyrrolidines and Methods of Use ABBVIE S.Á.R.L. (LU) 2019-10-17 US disclosed
US-10399940-B2 Substituted pyrrolidines and methods of use ABBVIE S.Á.R.L. (LU) 2019-09-03 US disclosed
EP-3523293-A1 SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS Abbvie S.a.r.l. (LU) 2019-08-14 EP disclosed
EP-3523277-A1 SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS Abbvie S.a.r.l. (LU) 2019-08-14 EP disclosed
US-9981910-B2 Substituted pyrrolidines and methods of use ABBVIE S.Á.R.L. (LU) 2018-05-29 US disclosed
WO-2018065921-A1 SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS ABBVIE S.Á.R.L. (LU) 2018-04-12 WO disclosed
US-20180099932-A1 Substituted Pyrrolidines and Methods of Use GALAPAGOS NV (BE) 2018-04-12 US disclosed
US-20180099931-A1 Substituted Pyrrolidines and Methods of Use ABBVIE S.Á.R.L. (LU) 2018-04-12 US disclosed
EP-1242410-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2002-09-25 EP disclosed
EP-0826684-B1 PIPERIDINE DERIVATIVES HISAMITSU PHARMACEUTICAL CO (JP) 2001-11-21 EP disclosed
WO-2001046174-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2001-06-28 WO disclosed
CN-1224423-A Process for preparing 2,3-dihydro-2-methyl-2-alkyl-benzofuran derivs KOREA RES INST CHEM TECH (KR) 1999-07-28 CN disclosed
EP-0912538-A1 PROCESS FOR PREPARING 2,3-DIHYDRO-2-METHYL-2-ALKYLBENZOFURAN DERIVATIVES KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 1999-05-06 EP disclosed
US-5886011-A TACHYKININ UNDECAPEPTIDE ANTAGONIST, USEFUL FOR TREATING ASTHMA, OR REMEDY FOR DISEASES ASSOCIATED WITH CENTRAL NERVOUS SYSTEM, DIGESTIVE SYSTEM AND CIRULATORY STYSTEM, AND VARIETY OF PAINS OR INFLAMMATION HISAMITSU PHARMACEUTICAL CO., INC. (JP) 1999-03-23 US disclosed
EP-0826684-A1 PIPERIDINE DERIVATIVES Hisamitsu Pharmaceutical Co., Inc. (JP) 1998-03-04 EP disclosed
WO-1997047615-A1 PROCESS FOR PREPARING 2,3-DIHYDRO-2-METHYL-2-ALKYLBENZOFURAN DERIVATIVES KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 1997-12-18 WO disclosed
US-4748186-A NEMATOCIDES, ANTHELMINTICS FMC CORPORATION (US) 1988-05-31 US disclosed
WO-1988000183-A1 S-TRIFLUOROBUTENYL DERIVATIVES AND PESTICIDAL USES FMC CORPORATION (US) 1988-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099931-A1 Substituted Pyrrolidines and Methods of Use CFTR, PKD1, PKD2 LMNA 3142/4885PKM 743/4885NPSR1 358/4885
US-20190315687-A1 Substituted Pyrrolidines and Methods of Use CFTR, PKD1, PKD2 LMNA 3325/4885PKM 793/4885NPSR1 319/4885
US-10399940-B2 Substituted pyrrolidines and methods of use CFTR, PKD1, PKD2 LMNA 3325/4885PKM 793/4885NPSR1 319/4885
US-20180099932-A1 Substituted Pyrrolidines and Methods of Use CFTR, PKD1, PKD2 LMNA 3325/4885PKM 793/4885NPSR1 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.